These findings have been replicated in five other cohorts (18, 35–39) and recently in a very large sample that also reported pre-existing neutralizing antibodies against lower concentrations (100 pg/mL) of IFN-α2 in 20% of COVID-19 deaths and 20% of critical cases in patients >80 years (19). This evidence concerns the gene IFNA2 and COVID-19.